Quantitation of dexfenfluramine/d-norfenfluramine concentration in primate brain using 19F NMR spectroscopy

Magnetic Resonance in Medicine

Volumn 39, Issue 1, 1998, Pages 149-154

  Christensen, James D ^a,b   Babb, Suzann M ^c   Cohen, Bruce M ^c   Renshaw, Perry F ^c  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NONE

Author keywords

Brain; Dexfenfluramine; Fluorine; Nuclear magnetic resonance

Indexed keywords

BIOMOLECULES; BRAIN; FLUORINE; GAS CHROMATOGRAPHY; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TISSUE;

ACTIVE METABOLITES; DEXFENFLURAMINE; DRUG DISTRIBUTION; HUMAN SUBJECTS; MAGNETIC RESONANCE SPECTROSCOPIES (MRS); MICROMOLAR RANGE; RELAXATION LOSS; STANDARD DEVIATION;

METABOLITES;

DEXFENFLURAMINE; NORFENFLURAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; DRUG BRAIN LEVEL; FEMALE; GAS CHROMATOGRAPHY; MACACA; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031975472     PISSN: 07403194     EISSN: None     Source Type: Journal    
DOI: 10.1002/mrm.1910390121     Document Type: Article

References (23)

1. R. J. Kuczmarski, Prevalence of overweight and weight gain in the United States. Am. J. Clin. Nutr. 55, 495S-502S (1992).
2. L. V. Sjostrom, Morbidity of severely obese subjects. Am. J. Clin. Nutr. 55, 508S-515S (1992).
3. E. A. Lew, Mortality and weight: insured lives and the American Cancer Society studies. Ann. Intern. Med. 103, 1024-1029 (1985).
4. F. W. Ashley, Jr., W. B. Kannel, Relation of weight change to changes in atherogenic traits: the Framingham study. J. Chronic Dis. 27, 104-114 (1974).
5. G. Enzi, G. Crepaldi, E. M. Inelmen, R. Bruni, B. Baggio, Efficacy and safety of dexfenfluramine in obese patients: a multicenter study. Clin. Neuropharmacol. 11(Suppl. 1), S173-S178 (1988).
6. N. Finer, D. Craddock, R. Lavielle, H. Keen, Effect of 6 months therapy with dexfenfluramine in obese patients: studies in the United Kingdom. Clin. Neuropharmacol. 11(Suppl. 1), S179-S186 (1988).
7. B. Guy-Grand, M. Apfelbaum, G. Crepaldi, A. Gries, P. Lefehyre, International trial of long-term dexfenfluramine in obesity. Lancet 2, 1142-1145 (1989).
8. D. McTavish, R. C. Heel, Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity [published erratum appears in Drugs 44(1), 8 (1992)]. Drugs 43(5), 713-733 (1992).
9. B. Guy-Grand, Clinical studies with dexfenfluramine: from past to future. Obes. Res. 3(Suppl), 491S-496S (1995).
10. G. A. Ricaurte, M. E. Molliver, M. B. Martello, J. L. Katz, M. A. Wilson, A. L. Martello, Dexfenfluramine neurotoxicity in brains of non-human primates. Lancet 338, 1487-1488 (1991).
11. U. McCann, G. Hatzidimitriou, A. Ridenour, C. Fischer, J. Yuan, J. Katz, G. Ricaurte, Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. J. Pharmacol. Exp. Ther. 269(2), 792-798 (1994).
12. R. Voelker, Obesity drug renews toxicity debate. JAMA 272, 1087-1088 (1994).
13. Deleted in proof.
14. A. Bergami, C. Fracasso, S. Garattini, S. Caccia, Brain uptake and acute indole-depleting effect of dexfenfluramine in squirrel monkeys after a high-dose regimen. Pharmacol. Sci. 1, 45-48 (1995).
15. A. Bergami, C. Fracasso, S. Caccia, The dexnorfenfluramine to dexfenfluramine plasma ratio in non-human primates. Pharmacol. Res. 31(Suppl), 46 (1995).
16. M. E. Ebifegha, R. F.. Code, J. E. Harrison, K. G. McNeill, M. Szyjkowski, In vivo analysis of bone content via NMR. Phys. Med. Biol. 32, 439-451 (1987).
17. P. F. Renshaw, A. R. Guimaraes, M. Fava, J. F. Rosenbaum, J. D. Pearlman, J. G. Flood, P. R. Puopolo, K. Clancy, R. G. Gonzalez, Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am. J. Psychiatry 149(11), 1592-1594 (1992).
18. 19F spin relaxation and localized spectroscopy of fluoxetino in human brain. Magn. Reson. Med. 31, 204-211 (1994).
19. L. A. Johnson, J. D. Pearlman, C. A. Miller, T. I. Young, K. R. Thulborn. MR quantification of cerebral ventricular volume using a semi-automated algorithm. AJNR 14(6), 1373-1378 (1993).
20. P. Lorrain, D. R. Corson, "Electromagnetic Fields and Waves," 2nd ed., W. H. Freeman and Company, San Francisco, 1970.
21. D. B. Campbell, The use of toxicokinetics for the safety assessment of drugs acting in the brain. Mol. Neurobiol. 11, 193-216 (1995).
22. R. Brownsill, D. Wallace, A. Taylor, B. Campbell, Study of human urinary metabolism of fenfluramine using gas chromatography-mass spectrometry. J. Chromatogr. 562(1-2), 267-277 (1991).
23. R. P. Richards, B. H. Gordon, R. M. Ings, D. B. Campbell, L. J. King, The measurement of d-fenfluramine and its metabolite, d-norfenfluramine in plasma and urine with an application of the method to pharmacokinetic studies. Xenobiotica 19(5), 547-553 (1989).